Rawcliffe Adrian — SEC Form 4 filings
SEC reporting owner CIK 1555851. 11 Form 4 filings on record with FilingPulse; latest filed 2026-08-13.
Transaction summary — filings shown
Covers all 11 filings on record, filed 2024-01-12 to 2026-08-13. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 11 legs across 7 filings — 229,571 shares, $911,344 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 10.
- Largest priced transaction: sale of 42,000 shares @ $15.00 ($630,000) in Wave Life Sciences, Inc., filed 2025-12-10.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Wave Life Sciences, Inc. (WVE) | Director | 5 | — | 3 legs · 70,815 sh · $806,604 | 6 |
| Adaptimmune Therapeutics PLC (ADAP) | Chief Executive Officer, Director | 6 | — | 8 legs · 158,756 sh · $104,740 | 4 |
Form 4 filings — Rawcliffe Adrian
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-13 | 4 | Wave Life Sciences, Inc. (WVE) | Sale (S): 12,700 @ $5.29 | EDGAR |
| 2025-12-10 | 4 | Wave Life Sciences Ltd. (WVE) | Option exercise (M): 42,000 @ $5.97 · Sale (S): 42,000 @ $15 · Option exercise (M): 42,000 (derivative) @ $0 | EDGAR |
| 2025-11-14 | 4 | Wave Life Sciences Ltd. (WVE) | Sale (S): 16,115 @ $6.79 | EDGAR |
| 2025-08-13 | 4 | Wave Life Sciences Ltd. (WVE) | Grant/award (A): 12,700 @ $0 · Grant/award (A): 76,200 (derivative) @ $0 | EDGAR |
| 2025-02-20 | 4 | Adaptimmune Therapeutics PLC (ADAP) | Grant/award (A): 5,143,248 (derivative) @ $0 · Grant/award (A): 3,428,832 (derivative) @ $0 | EDGAR |
| 2025-01-17 | 4 | Adaptimmune Therapeutics PLC (ADAP) | Sale (S): 30,601 @ $0.58 | EDGAR |
| 2025-01-15 | 4 | Adaptimmune Therapeutics PLC (ADAP) | Sale (S): 12,539 @ $0.59 · Sale (S): 17,934 @ $0.59 · Sale (S): 29,096 @ $0.57 | EDGAR |
| 2024-08-14 | 4 | Wave Life Sciences Ltd. (WVE) | Grant/award (A): 16,115 @ $0 · Grant/award (A): 32,230 (derivative) @ $0 | EDGAR |
| 2024-01-17 | 4 | Adaptimmune Therapeutics PLC (ADAP) | Grant/award (A): 7,633,296 (derivative) @ $0 · Grant/award (A): 1,696,272 (derivative) @ $0 | EDGAR |
| 2024-01-17 | 4 | Adaptimmune Therapeutics PLC (ADAP) | Sale (S): 9,304 @ $0.79 · Sale (S): 30,080 @ $0.67 | EDGAR |
| 2024-01-12 | 4 | Adaptimmune Therapeutics PLC (ADAP) | Sale (S): 11,945 @ $0.84 · Sale (S): 17,257 @ $0.85 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1555851 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →